Global Guide of Coming Off-patent Agrochemical Active Ingredients

Report edition: 2019 edition(6)
Finished time: Jun. 2019
Document type: PDF
Total pages : 133
Language version: English
Published by CCM

Single user license: -56% $ 1,100.00
List Price $ 2,500.00

Corporate license: -56% $ 2,750.00
List Price $ 6,250.00

All the prices on this website exclude VAT.

CCM_sample_Global Guide of Coming Off-patent Agrochemical Active Ingredients

Introduction
Main contents
List of tables
List of figures

Description:

As a good guide for pesticide companies who are interested in commercial development of coming off-patent products, this report is CCM's sixth edition report on coming off-patent agrochemicals in the world.

This report contains profiles of 28 active ingredients (12 herbicides, 6 insecticides, 9 fungicides and 1 safener) whose patents will expire in 2019–2024.

Among the 28 active ingredients, none of the two, namely flufenpyr-ethyl, pyrifluquinazon, had been registered in 15 target countries as of April 2019, while nine of them had been registered in equal to or more than ten countries among the 15 target ones.

Among the 15 target countries, there were nine countries where at least 15 active ingredients were registered as of April 2019—Argentina, Australia, Canada, China, Belgium, France, Greece, the Netherlands and South Africa.

The data from various channels have been combined to make this report as precise and scientific as possible. Throughout the process, a series of internal discussions were held in order to analyse the data and draw conclusions from it.

The coming off-patent active ingredients are expected to add value to the pesticide market. Compared with developing new varieties of pesticides, to develop the pesticides whose patents have expired will not only cost less and have lower risk, but also enjoy considerable profits. In a word, it will be a huge market with tremendous commercial value.

As for each active ingredient, this report introduces its basic information, chemical structure, history, application, physical & safety data, patent information, registration information in 15 target countries (Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Denmark, Finland, France, Greece, the Netherlands, South Africa, Switzerland and Uruguay), etc.

Readers of this report can:

- gain an overview of the coming off-patent products whose patents will be expired in 2019–2024;

- know the registration situation of the hot products of agricultural giants in main agricultural countries.

To enquire about this report, please email econtact@cnchemicals.com or call +86-20-37616606.

Main contents:

(The price of report chapters below is for single user license, please contact us if you want to update to corporate license.)

No.	Content	Page	Price
	Executive summary	1	$ 150
	Methodology and scope	5	$ 25
1	Profiles of coming off-patent herbicides	7	$ 1,000
1-1	Aminopyralid	7	$ 100
1-2	Flucetosulfuron	12	$ 75
1-3	Flufenpyr-ethyl	15	$ 75
1-4	Metamifop	17	$ 75
1-5	Pinoxaden	20	$ 100
1-6	Pyrasulfotole	27	$ 75
1-7	Pyroxasulfone	30	$ 75
1-8	Pyroxsulam	32	$ 100
1-9	Saflufenacil	39	$ 100
1-10	Tembotrione	42	$ 100
1-11	Thiencarbazone-methyl	47	$ 100
1-12	Indaziflam	53	$ 100
2	Profiles of coming off-patent insecticides	57	$ 625
2-1	Chlorantraniliprole	57	$ 100
2-2	Flubendiamide	62	$ 100
2-3	Metofluthrin	66	$ 100
2-4	Pyrifluquinazon	69	$ 100
2-5	Cyantraniliprole	70	$ 125
2-6	Cyflumetofen	75	$ 125
3	Profiles of coming off-patent fungicides	78	$ 750
3-1	Fenpyrazamine	78	$ 75
3-2	Fluopicolide	80	$ 75
3-3	Mandipropamid	87	$ 75
3-4	Penflufen	94	$ 75
3-5	Valifenalate	98	$ 75
3-6	Bixafen	101	$ 75
3-7	Fluopyram	107	$ 75
3-8	Isopyrazam	114	$ 100
3-9	Sedaxane	118	$ 100
4	Others	124	$ 100
4-1	Cyprosulfamide	124	$ 125

successfully!

CheckOut

List of tables:

Table No.	Table Title
Table 1.1-1	Patent information of aminopyralid in some countries/regions, as of April 2019
Table 1.1-2	Registration information of aminopyralid in China, as of April 2019
Table 1.1-3	Registration information of aminopyralid in Finland, as of April 2019
Table 1.1-4	Registration information of aminopyralid in Denmark, as of April 2019
Table 1.1-5	Registration information of aminopyralid in Canada, as of April 2019
Table 1.1-6	Registration information of aminopyralid in France, as of April 2019
Table 1.1-7	Registration information of aminopyralid in Uruguay, as of April 2019
Table 1.1-8	Registration information of aminopyralid in Australia, as of April 2019
Table 1.1-9	Registration information of aminopyralid in Switzerland, as of April 2019
Table 1.1-10	Registration information of aminopyralid in Argentina, as of April 2019
Table 1.1-11	Registration information of aminopyralid in South Africa, as of April 2019
Table 1.1-12	Registration information of aminopyralid in Belgium, as of April 2019
Table 1.1-13	Registration information of aminopyralid in Greece, as of April 2019
Table 1.2-1	Patent information of flucetosulfuron in some countries/regions, as of April 2019
Table 1.2-2	Registration information of flucetosulfuron in China, as of April 2019
Table 1.3-1	Patent information of flufenpyr-ethyl in some countries/regions, as of April 2019
Table 1.4-1	Patent information of metamifop in some countries/regions, as of April 2019
Table 1.4-2	Registration information of metamifop in China, as of April 2019
Table 1.4-3	Registration information of metamifop in Uruguay, as of April 2019
Table 1.5-1	Patent information of pinoxaden in some countries/regions, as of April 2019
Table 1.5-2	Registration information of pinoxaden in Argentina, as of April 2019
Table 1.5-3	Registration information of pinoxaden in South Africa, as of April 2019
Table 1.5-4	Registration information of pinoxaden in Australia, as of April 2019
Table 1.5-5	Registration information of pinoxaden in Belgium, as of April 2019
Table 1.5-6	Registration information of pinoxaden in Canada, as of April 2019
Table 1.5-7	Registration information of pinoxaden in Chile, as of April 2019
Table 1.5-8	Registration information of pinoxaden in China, as of April 2019
Table 1.5-9	Registration information of pinoxaden in Finland, as of April 2019
Table 1.5-10	Registration information of pinoxaden in France, as of April 2019
Table 1.5-11	Registration information of pinoxaden in Greece, as of April 2019
Table 1.5-12	Registration information of pinoxaden in the Netherlands, as of April 2019
Table 1.5-13	Registration information of pinoxaden in Switzerland, as of April 2019
Table 1.5-14	Registration information of pinoxaden in Uruguay, as of April 2019
Table 1.6-1	Patent information of pyrasulfotole in some countries/regions, as of April 2019
Table 1.6-2	Registration information of pyrasulfotole in Canada, as of April 2019
Table 1.6-3	Registration information of pyrasulfotole in Australia, as of April 2019
Table 1.6-4	Registration information of pyrasulfotole in South Africa, as of April 2019
Table 1.7-1	Patent information of pyroxasulfone in some countries/regions, as of April 2019
Table 1.7-2	Registration information of pyroxasulfone in Canada, as of April 2019
Table 1.7-3	Registration information of pyroxasulfone in Australia, as of April 2019
Table 1.7-4	Registration information of pyroxasulfone in South Africa, as of April 2019
Table 1.7-5	Registration information of pyroxasulfone in Argentina, as of April 2019
Table 1.7-6	Registration information of pyroxasulfone in China, as of April 2019
Table 1.8-1	Patent information of pyroxsulam in some countries/regions, as of April 2019
Table 1.8-2	Registration information of pyroxsulam in China, as of April 2019
Table 1.8-3	Registration information of pyroxsulam in Belgium, as of April 2019
Table 1.8-4	Registration information of pyroxsulam in Brazil, as of April 219
Table 1.8-5	Registration information of pyroxsulam in Canada, as of April 2019
Table 1.8-6	Registration information of pyroxsulam in France, as of April 2019
Table 1.8-7	Registration information of pyroxsulam in the Netherlands, as of April 2019
Table 1.8-8	Registration information of pyroxsulam in Australia, as of April 2019
Table 1.8-9	Registration information of pyroxsulam in Switzerland, as of April 2019
Table 1.8-10	Registration information of pyroxsulam in Denmark, as of April 2019
Table 1.8-11	Registration information of pyroxsulam in Finland, as of April 2019
Table 1.8-12	Registration information of pyroxsulam in Greece, as of April 2019
Table 1.8-13	Registration information of pyroxsulam in South Africa, as of April 2019
Table 1.9-1	Patent information of saflufenacil in some countries/regions, as of April 2019
Table 1.9-2	Registration information of saflufenacil in China, as of April 2019
Table 1.9-3	Registration information of saflufenacil in Brazil, as of April 2019
Table 1.9-4	Registration information of saflufenacil in Canada, as of April 2019
Table 1.9-5	Registration information of saflufenacil in Uruguay, as of April 2019
Table 1.9-6	Registration information of saflufenacil in Australia, as of April 2019
Table 1.9-7	Registration information of saflufenacil in Chile, as of April 2019
Table 1.9-8	Registration information of saflufenacil in Argentina, as of April 2019
Table 1.9-9	Registration information of saflufenacil in South Africa, as of April 2019
Table 1.10-1	Patent information of tembotrione in some countries/regions, as of April 2019
Table 1.10-2	Registration information of tembotrione in Belgium, as of April 2019
Table 1.10-3	Registration information of tembotrione in South Africa, as of April 2019
Table 1.10-4	Registration information of tembotrione in Canada, as of April 2019
Table 1.10-5	Registration information of tembotrione in Chile, as of April 2019
Table 1.10-6	Registration information of tembotrione in France, as of April 2019
Table 1.10-7	Registration information of tembotrione in the Netherlands, as of April 2019
Table 1.10-8	Registration information of tembotrione in Switzerland, as of April 2019
Table 1.10-9	Registration information of tembotrione in Greece, as of April 2019
Table 1.11-1	Patent information of thiencarbazone-methyl in some countries/regions, as of April 2019
Table 1.11-2	Registration information of thiencarbazone-methyl in Belgium, as of April 2019
Table 1.11-3	Registration information of thiencarbazone-methyl in Canada, as of April 2019
Table 1.11-4	Registration information of thiencarbazone-methyl in France, as of April 2019
Table 1.11-5	Registration information of thiencarbazone-methyl in the Netherlands, as of April 2019
Table 1.11-6	Registration information of thiencarbazone-methyl in Uruguay, as of April 2019
Table 1.11-7	Registration information of thiencarbazone-methyl in China, as of April 2019
Table 1.11-8	Registration information of thiencarbazone-methyl in Denmark, as of April 2019
Table 1.11-9	Registration information of thiencarbazone-methyl in Argentina, as of April 2019
Table 1.11-10	Registration information of Thiencarbazone-methyl in Finland, as of April 2019
Table 1.11-11	Registration information of thiencarbazone-methyl in Greece, as of April 2019
Table 1.11-12	Registration information of thiencarbazone-methyl in Switzerland, as of April 2019
Table 1.12-1	Patent information of indaziflam in some countries/regions, as of April 2019
Table 1.12-2	Registration information of indaziflam in Argentina, as of April 2019
Table 1.12-3	Registration information of indaziflam in Australia, as of April 2019
Table 1.12-4	Registration information of indaziflam in Brazil, as of April 2019
Table 1.12-5	Registration information of indaziflam in Canada, as of April 2019
Table 1.12-6	Registration information of indaziflam in South Africa, as of April 2019
Table 1.12-7	Registration information of indaziflam in Uruguay, as of April 2019
Table 2.1-1	Patent information of chlorantraniliprole in some countries/regions, as of April 2019
Table 2.1-2	Registration information of chlorantraniliprole in China, as of April 2019
Table 2.1-3	Registration information of chlorantraniliprole in Canada, as of April 2019
Table 2.1-4	Registration information of chlorantraniliprole in France, as of April 2019
Table 2.1-5	Registration information of chlorantraniliprole in the Netherlands, as of April 2019
Table 2.1-6	Registration information of chlorantraniliprole in Australia, as of April 2019
Table 2.1-7	Registration information of chlorantraniliprole in Switzerland, as of April 2019
Table 2.1-8	Registration information of chlorantraniliprole in South Africa, as of April 2019
Table 2.1-9	Registration information of chlorantraniliprole in Greece, as of April 2019
Table 2.2-1	Patent information of flubendiamide in some countries/regions, as of April 2019
Table 2.2-2	Registration information of flubendiamide in Argentina, as of April 2019
Table 2.2-3	Registration information of flubendiamide in Australia, as of April 2019
Table 2.2-4	Registration information of flubendiamide in South Africa, as of April 2019
Table 2.2-5	Registration information of flubendiamide in Chile, as of April 2019
Table 2.2-6	Registration information of flubendiamide in China, as of April 2019
Table 2.2-7	Registration information of flubendiamide in Uruguay, as of April 2019
Table 2.3-1	Patent information of metofluthrin in some countries/regions, as of April 2019
Table 2.3-2	Registration information of metofluthrin in Australia, as of April 2019
Table 2.3-3	Registration information of metofluthrin in Canada, as of April 2019
Table 2.3-4	Registration information of metofluthrin in China, as of April 2019
Table 2.3-5	Registration information of metofluthrin in the Netherlands, as of April 2019
Table 2.3-6	Registration information of metofluthrin in South Africa, as of April 2019
Table 2.4-1	Patent information of pyrifluquinazon in some countries/regions, as of April 2019
Table 2.5-1	Patent information of cyantraniliprole in some countries/regions, as of April 2019
Table 2.5-2	Registration information of cyantraniliprole in China, as of April 2019
Table 2.5-3	Registration information of cyantraniliprole in Canada, as of April 2019
Table 2.5-4	Registration information of cyantraniliprole in Australia, as of April 2019
Table 2.5-5	Registration information of cyantraniliprole in the Netherlands, as of April 2019
Table 2.5-6	Registration information of cyantraniliprole in Belgium, as of April 2019
Table 2.5-7	Registration information of cyantraniliprole in Argentina, as of April 2019
Table 2.5-8	Registration information of cyantraniliprole in France, as of April 2019
Table 2.5-9	Registration information of cyantraniliprole in South Africa, as of April 2019
Table 2.6-1	Patent informulation of cyflumetofen in some countries/regions, as of April 2019
Table 2.6-2	Registration information of cyflumetofen in China, as of April 2019
Table 2.6-3	Registration information of cyflumetofen in Brazil, as of April 2019
Table 2.6-4	Registration information of cyflumetofen in Canada, as of April 2019
Table 2.6-5	Registration information of cyflumetofen in the Netherlands, as of April 2019
Table 2.6-6	Registration information of cyflumetofen in Belgium, as of April 2019
Table 2.6-7	Registration information of cyflumetofen in Argentina, as of April 2019
Table 2.6-8	Registration information of cyflumetofen in Greece, as of April 2019
Table 3.1-1	Patent information of fenpyrazamine in some countries/regions, as of April 2019
Table 3.1-2	Registration information of fenpyrazamine in Australia, as of April 2019
Table 3.1-3	Registration information of fenpyrazamine in Chile, as of April 2019
Table 3.1-4	Registration information of fenpyrazamine in Denmark, as of April 2019
Table 3.1-5	Registration information of fenpyrazamine in Belgium, as of April 2019
Table 3.1-6	Registration information of fenpyrazamine in France, as of April 2019
Table 3.1-7	Registration information of fenpyrazamine in the Netherlands, as of April 2019
Table 3.1-8	Registration information of fenpyrazamine in Finland, as of April 2019
Table 3.1-9	Registration information of fenpyrazamine in Switzerland, as of April 2019
Table 3.1-10	Registration information of fenpyrazamine in Greece, as of April 2019
Table 3.2-1	Patent information of fluopicolide in some countries/regions, as of April 2019
Table 3.2-2	Registration information of fluopicolide in Argentina, as of April 2019
Table 3.2-3	Registration information of fluopicolide in Australia, as of April 2019
Table 3.2-4	Registration information of fluopicolide in South Africa, as of April 2019
Table 3.2-5	Registration information of fluopicolide in Belgium, as of April 2019
Table 3.2-6	Registration information of fluopicolide in Brazil, as of April 2019
Table 3.2-7	Registration information of fluopicolide in Canada, as of April 2019
Table 3.2-8	Registration information of fluopicolide in Chile, as of April 2019
Table 3.2-9	Registration information of fluopicolide in China, as of April 2019
Table 3.2-10	Registration information of fluopicolide in Finland, as of April 2019
Table 3.2-11	Registration information of fluopicolide in France, as of April 2019
Table 3.2-12	Registration information of fluopicolide in the Netherlands, as of April 2019
Table 3.2-13	Registration information of fluopicolide in Switzerland, as of April 2019
Table 3.2-14	Registration information of fluopicolide in Uruguay, as of April 2019
Table 3.2-15	Registration information of fluopicolide in Greece, as of April 2019
Table 3.3-1	Patent information of mandipropamid in some countries/regions, as of April 2019
Table 3.3-2	Registration information of mandipropamid in Belgium, as of April 2019
Table 3.3-3	Registration information of mandipropamid in Brazil, as of April 2019
Table 3.3-4	Registration information of mandipropamid in China, as of April 2019
Table 3.3-5	Registration information of mandipropamid in Canada, as of April 2019
Table 3.3-6	Registration information of mandipropamid in France, as of April 2019
Table 3.3-7	Registration information of mandipropamid in Finland, as of April 2019
Table 3.3-8	Registration information of mandipropamid in the Netherlands, as of April 2019
Table 3.3-9	Registration information of mandipropamid in Australia, as of April 2019
Table 3.3-10	Registration information of mandipropamid in Switzerland, as of April 2019
Table 3.3-11	Registration information of mandipropamid in Denmark, as of April 2019
Table 3.3-12	Registration information of mandipropamid in Chile, as of April 2019
Table 3.3-13	Registration information of mandipropamid in Argentina, as of April 2019
Table 3.3-14	Registration information of mandipropamid in South Africa, as of April 2019
Table 3.3-15	Registration information of mandipropamid in Greece, as of April 2019
Table 3.4-1	Patent information of penflufen in some countries/regions, as of April 2019
Table 3.4-2	Registration information of penflufen in Canada, as of April 2019
Table 3.4-3	Registration information of penflufen in the Netherlands, as of April 2019
Table 3.4-4	Registration information of penflufen in Australia, as of April 2019
Table 3.4-5	Registration information of penflufen in Finland, as of April 2019
Table 3.4-6	Registration information of penflufen in Belgium, as of April 2019
Table 3.4-7	Registration information of penflufen in Chile, as of April 2019
Table 3.5-1	Patent information of valifenalate in some countries/regions, as of April 2019
Table 3.5-2	Registration information of valifenalate in Belgium, as of April 2019
Table 3.5-3	Registration information of valifenalate in France, as of April 2019
Table 3.5-4	Registration information of valifenalate in Switzerland, as of April 2019
Table 3.5-5	Registration information of valifenalate in Chile, as of April 2019
Table 3.5-6	Registration information of valifenalate in Greece, as of April 2019
Table 3.5-7	Registration information of valifenalate in South Africa, as of April 2019
Table 3.6-1	Patent information of bixafen in some countries/regions, as of April 2019
Table 3.6-2	Registration information of bixafen in Argentina, as of April 2019
Table 3.6-3	Registration information of bixafen in Australia, as of April 2019
Table 3.6-4	Registration information of bixafen in Belgium, as of April 2019
Table 3.6-5	Registration information of bixafen in Chile, as of April 2019
Table 3.6-6	Registration information of bixafen in Denmark, as of April 2019
Table 3.6-7	Registration information of bixafen in Finland, as of April 2019
Table 3.6-8	Registration information of bixafen in France, as of April 2019
Table 3.6-9	Registration information of bixafen in the Netherlands, as of April 2019
Table 3.6-10	Registration information of bixafen in South Africa, as of April 2019
Table 3.6-11	Registration information of bixafen in Switzerland, as of April 2019
Table 3.6-12	Registration information of bixafen in Uruguay, as of April 2019
Table 3.7-1	Patent information of fluopyram in some countries/regions, as of April 2019
Table 3.7-2	Registration information of fluopyram in Australia, as of April 2019
Table 3.7-3	Registration information of fluopyram in Belgium, as of April 2019
Table 3.7-4	Registration information of fluopyram in Canada, as of April 2019
Table 3.7-5	Registration information of fluopyram in China, as of April 2019
Table 3.7-6	Registration information of fluopyram in Denmark, as of April 2019
Table 3.7-7	Registration information of fluopyram in Finland, as of April 2019
Table 3.7-8	Registration information of fluopyram in France, as of April 2019
Table 3.7-9	Registration information of fluopyram in Greece, as of April 2019
Table 3.7-10	Registration information of fluopyram in the Netherlands, as of April 2019
Table 3.7-11	Registration information of fluopyram in South Africa, as of April 2019
Table 3.7-12	Registration information of fluopyram in Switzerland, as of April 2019
Table 3.8-1	Patent information of isopyrazam in some countries/regions, as of April 2019
Table 3.8-2	Registration information of isopyrazam in Argentina, as of April 2019
Table 3.8-3	Registration information of isopyrazam in Australia, as of April 2019
Table 3.8-4	Registration information of isopyrazam in Belgium, as of April 2019
Table 3.8-5	Registration information of isopyrazam in China, as of April 2019
Table 3.8-6	Registration information of isopyrazam in France, as of April 2019
Table 3.8-7	Registration information of isopyrazam in Greece, as of April 2019
Table 3.8-8	Registration information of isopyrazam in the Netherlands, as of April 2019
Table 3.8-9	Registration information of isopyrazam in Uruguay, as of April 2019
Table 3.9-1	Patent information of sedaxane in some countries/regions, as of April 2019
Table 3.9-2	Registration information of sedaxane in Argentina, as of April 2019
Table 3.9-3	Registration information of sedaxane in Australia, as of April 2019
Table 3.9-4	Registration information of sedaxane in Canada, as of April 2019
Table 3.9-5	Registration information of sedaxane in Chile, as of April 2019
Table 3.9-6	Registration information of sedaxane in China, as of April 2019
Table 3.9-7	Registration information of sedaxane in Denmark, as of April 2019
Table 3.9-8	Registration information of sedaxane in Finland, as of April 2019
Table 3.9-9	Registration information of sedaxane in France, as of April 2019
Table 3.9-10	Registration information of sedaxane in Greece, as of April 2019
Table 3.9-11	Registration information of sedaxane in Uruguay, as of April 2019
Table 4.1-1	Patent information of cyprosulfamide in some countries/regions, as of April 2019
Table 4.1-2	Registration information of cyprosulfamide in Belgium, as of April 2019
Table 4.1-3	Registration information of cyprosulfamide in Canada, as of April 2019
Table 4.1-4	Registration information of cyprosulfamide in Argentina, as of April 2019
Table 4.1-5	Registration information of cyprosulfamide in the Netherlands, as of April 2019
Table 4.1-6	Registration information of cyprosulfamide in Greece, as of April 2019

List of figures:

Figure No.	Figure Title
Figure 1.1-1	Chemical structure of aminopyralid
Figure 1.2-1	Chemical structure of flucetosulfuron
Figure 1.2-2	Route for synthesizing flucetosulfuron
Figure 1.3-1	Chemical structure of flufenpyr-ethyl
Figure 1.3-2	Route for synthesizing flufenpyr-ethyl
Figure 1.4-1	Chemical structure of metamifop
Figure 1.4-2	Route A for synthesizing metamifop
Figure 1.4-3	Route B for synthesizing metamifop
Figure 1.4-4	Route C for synthesizing metamifop
Figure 1.5-1	Chemical structure of pinoxaden
Figure 1.5-2	Route for synthesizing pinoxaden
Figure 1.6-1	Chemical structure of pyrasulfotole
Figure 1.7-1	Chemical structure of Pyroxasulfone
Figure 1.8-1	Chemical structure of pyroxsulam
Figure 1.9-1	Chemical structure of saflufenacil
Figure 1.10-1	Chemical structure of tembotrione
Figure 1.10-2	Route for synthesizing tembotrione
Figure 1.11-1	Chemical structure of thiencarbazone-methyl
Figure 2.1-1	Chemical structure of chlorantraniliprole
Figure 2.2-1	Chemical structure of flubendiamide
Figure 2.3-1	Chemical structure of metofluthrin
Figure 2.3-2	Route for synthesizing metofluthrin
Figure 2.4-1	Chemical structure of pyrifluquinazon
Figure 2.5-1	Chemical structure of cyantraniliprole
Figure 2.6-1	Chemistry structure of cyflumetofen
Figure 3.1-1	Chemical structure of fenpyrazamine
Figure 3.2-1	Chemical structure of fluopicolide
Figure 3.2-2	Route A for synthesizing fluopicolide
Figure 3.2-3	Route B for synthesizing fluopicolide
Figure 3.3-1	Chemical structure of mandipropamid
Figure 3.4-1	Chemical structure of penflufen
Figure 3.5-1	Chemical structure of valifenalate
Figure 3.6-1	Chemical structure of bixafen
Figure 3.7-1	Chemical structure of fluopyram
Figure 3.8-1	Chemical structure of isopyrazam
Figure 3.9-1	Chemical structure of sedaxane
Figure 4.1-1	Chemical structure of cyprosulfamide

CCM Customized Service on Market Research

Do you want Import & Export Analysis, Financial Data, Cost Analysis, Supply Chain Research etc. ? We will customize the specific research for you, in case the services listed above does not meet your precise requirements. Our product and industry research in China’s agriculture, chemicals, food & ingredients and life science markets will comprehensively cover the business information, which is able to help you arrive at strategic and profitable business decisions.

Please directly contact econtact@cnchemicals.com to specify your Market Research Requirement

SAMPLE DOWNLOAD

In order to provide you with access to all the free content on this site, we would like you to tell us who you are.
Please enter the following - you will only have to do this once. Or if you already have an account, please sign in here.

* Name
* Your E-mail address
* Your phone number
Your company
* Your industry

Recommend Report

Need some help to find your information ?

Search Report

Recommend Newsletter

Related market data

Related product

Related research

Global Guide of Coming Off-patent Agrochemical Active Ingredients

Single user license: -56% $ 1,100.00
List Price $ 2,500.00

Corporate license: -56% $ 2,750.00
List Price $ 6,250.00

All the prices on this website exclude VAT.

Description:

Main contents:

List of tables:

List of figures:

CCM Customized Service on Market Research

SAMPLE DOWNLOAD

My Products (0 items)

Login/Register

Recommend Report

Need some help to find your information ?

Search Report

Recommend Newsletter

Related market data

Related product

Related research

Global Guide of Coming Off-patent Agrochemical Active Ingredients

Single user license: -56% $ 1,100.00 List Price $ 2,500.00 Corporate license: -56% $ 2,750.00 List Price $ 6,250.00 All the prices on this website exclude VAT.

Description:

Main contents:

List of tables:

List of figures:

CCM Customized Service on Market Research

SAMPLE DOWNLOAD

Single user license: -56% $ 1,100.00
List Price $ 2,500.00

Corporate license: -56% $ 2,750.00
List Price $ 6,250.00

All the prices on this website exclude VAT.